{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Defined as the proportion of patients who experience CMV reactivation (CMV deoxyribonucleic acid \\[DNA\\] by real time polymerase chain reaction \\> 500 IU/mL) during prophylaxis period among all patients who receive \\>= 90% of planned letermovir doses. The rate will be provided with 95% binomial confidence interval.","groups":[{"description":"Beginning within 7 days of the first administration of standard alemtuzumab, patients receive letermovir PO (or IV over 1 hour if patient is unable to take PO for an extended period of time) daily on days 1-28. Cycles repeat every 28 days for up to 3 months after the last dose of alemtuzumab in the absence of unacceptable toxicity.\n\nLetermovir: Given PO","id":"OG000","title":"Treatment (Letermovir)"}],"populationDescription":"Data for this outcome was not collected","reportingStatus":"POSTED","timeFrame":"During prophylaxis treatment (3 months after last dose of alemtuzumab)","title":"Cytomegalovirus (CMV) Reactivation","type":"PRIMARY"}